Aspirin for prevention and treatment of cardiovascular disease

Annals of Internal Medicine

Volumn 150, Issue 6, 2009, Pages 414-416

  Mehta, Shamir R ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; BLEEDING TENDENCY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HUMAN; ISCHEMIA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; STROKE; THROMBOSIS; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE;

EID: 62549128628     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-6-200903170-00011     Document Type: Review

References (12)

1. Steinhubl SR, Bhatt DL, Brennan DM, Montalescot G, Hankey GJ, Eikelboom JW, et al; CHARISMA Investigators. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379-86.
2. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396-404.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. [PMID: 11786451]
4. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682-7. [PMID: 14504182]
5. Jolly SS, Pogue J, Haladyn K, Peters RJ, Fox KA, Avezum A, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J. 2008. [PMID: 18819961]
6. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, et al; Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399-406. [PMID: 12874182]
7. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17. [PMID: 16531616]
8. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, et al; CURRENT-OASIS 7 Steering Committee. Design and rationale of CURRENT- OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J. 2008;156:1080-1088.e1. [PMID: 19033002]
9. Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events/Optimal Antiplatelet Strategy for Interventions (CURRENT/OASIS7). Accessed at www.clinicaltrials.gov on 17 February 2009.
10. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-72. [PMID: 11790072]
11. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304. [PMID: 15753114]
12. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006; 295:306-13. [PMID: 16418466]